Laura C. Cappelli - Concepedia

Author

Laura C. Cappelli

Also Known As

Cappelli, Laura, Clifton Bingham, L CAPPELLI, L Cappelli, L. Cappelli, Laura C Cappelli, Laura C. Cappelli, Laura Cappelli

118

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center Massachusetts General Hospital Center for Rheumatology

About

Laura C. Cappelli is an author at Johns Hopkins University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.4K
2	Allergy	3	3	259
3	Epidemiology	2	2	72
4	Public Health	1	1	53
5	Cell Biology	1	1	49

Laura C. Cappelli

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Journal for ImmunoTherapy of Cancer Cancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsCancer ManagementImmunology	2021	748
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab Laura C. Cappelli, Anna Kristina Gutierrez, Alan N. Baer, Annals of the Rheumatic Diseases	2016	384
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation Tawnie Braaten, Julie R. Brahmer, Patrick M. Forde, Annals of the Rheumatic Diseases	2019	217
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis Karthik Suresh, Jarushka Naidoo, Qiong Zhong, Journal of Clinical Investigation	2019	186
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy Blake M. Warner, Alan N. Baer, Evan J. Lipson, The Oncologist	2019	171
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen Laura C. Cappelli, Julie R. Brahmer, Patrick M. Forde, Seminars in Arthritis and Rheumatism InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseAllergy	2018	153
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry Joel M. Kremer, Clifton O. Bingham, Laura C. Cappelli, ACR Open Rheumatology	2021	135
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, Journal for ImmunoTherapy of Cancer Consensus DefinitionsTranslational MedicineCancer ImmunosurveillanceMedicineImmunology	2023	117
A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events Jarushka Naidoo, Jiajia Zhang, Evan J. Lipson, Journal of the National Comprehensive Cancer Network	2019	105
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis Laura C. Cappelli, M. Tevfik Dorak, Maria Bettinotti, Lara D. Veeken	2018	104

Page 1